We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.32%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$875M
AUM Growth
-$123M
Cap. Flow
+$83.4M
Cap. Flow %
9.54%
Top 10 Hldgs %
28.77%
Holding
95
New
7
Increased
32
Reduced
30
Closed
6

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$14M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$11.4M
3
CNC icon
Centene
CNC
+$10.7M
4
BIIB icon
Biogen
BIIB
+$9.57M
5
UNH icon
UnitedHealth
UNH
+$9.35M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$10.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.4M
3
INCY icon
Incyte
INCY
+$7.17M
4
LOXO
Loxo Oncology, Inc
LOXO
+$6.07M
5
EXEL icon
Exelixis
EXEL
+$5.39M

Sector Composition

Rank Sector Weight
1 Healthcare 93.94%
2 Energy 0.12%
3 Technology 0.11%
4 Financials 0.09%
5 Communication Services 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$31.5M 3.6%
126,396
+35,396
+39% +$9.35M
CI icon
2
Cigna
CI
$73.7B
$30.3M 3.47%
159,691
-15,000
-9% -$3.13M
MDT icon
3
Medtronic
MDT
$109B
$27.3M 3.12%
300,403
+50,529
+20% +$4.72M
CVS icon
4
CVS Health
CVS
$133B
$26.8M 3.06%
408,868
-30,000
-7% -$2.24M
BDX icon
5
Becton Dickinson
BDX
$45.6B
$25.9M 2.96%
117,875
+35,875
+44% +$8.33M
HUM icon
6
Humana
HUM
$43.7B
$23.6M 2.7%
82,400
+29,400
+55% +$9.32M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$22.4M 2.56%
230,429
-12,900
-5% -$1.52M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$121B
$21.9M 2.51%
132,425
-10,040
-7% -$1.74M
ABMD
9
DELISTED
Abiomed Inc
ABMD
$21.2M 2.43%
65,310
+9,609
+17% +$3.34M
ELV icon
10
Elevance Health
ELV
$81.5B
$20.7M 2.36%
78,645
+8,645
+12% +$2.38M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$20.6M 2.35%
165,818
+39,496
+31% +$5.86M
BMY icon
12
Bristol-Myers Squibb
BMY
$133B
$19.2M 2.2%
370,000
+40,000
+12% +$2.15M
ABT icon
13
Abbott
ABT
$183B
$19.1M 2.19%
264,552
– –
EXEL icon
14
Exelixis
EXEL
$13.3B
$18.9M 2.16%
958,994
-302,420
-24% -$5.39M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$18.5M 2.11%
946,060
+29,009
+3% +$569K
NVCR icon
16
NovoCure
NVCR
$1.73B
$18.2M 2.09%
545,000
+145,000
+36% +$5.3M
BIIB icon
17
Biogen
BIIB
$30B
$18.1M 2.06%
60,000
+30,000
+100% +$9.57M
INCY icon
18
Incyte
INCY
$24.2B
$16.9M 1.94%
266,416
-110,500
-29% -$7.17M
NKTR icon
19
Nektar Therapeutics
NKTR
$2.39B
$16.9M 1.94%
34,333
+13,973
+69% +$8.43M
ESPR
20
DELISTED
Esperion Therapeutics
ESPR
$16.3M 1.86%
353,961
– –
DPLO
21
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$16.2M 1.85%
1,203,405
+28,994
+2% +$489K
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.6B
$15M 1.72%
176,549
-88,300
-33% -$8.4M
ABBV icon
23
AbbVie
ABBV
$443B
$15M 1.71%
162,415
+32,415
+25% +$2.85M
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
$14.5M 1.66%
371,858
+5,471
+1% +$215K
NBIX icon
25
Neurocrine Biosciences
NBIX
$16.8B
$14.4M 1.64%
201,091
+119,414
+146% +$11.4M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rhenman & Partners Asset Management held 95 positions worth $875M, down 12% from $998M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $83.4M of net new capital in Q4 2018, opening 7 new positions and adding to 32 existing holdings. Its largest new stake was bluebird bio: 9,098 shares worth $11.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $8.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2018 buy was bluebird bio: 9,098 shares worth $11.7M.
  • Rhenman & Partners Asset Management added most to Neurocrine Biosciences in Q4 2018, an estimated $11.4M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2018 reduction was BioMarin Pharmaceuticals, cutting an estimated $8.4M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2018, selling an estimated $10.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $875M portfolio in Q4 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 6 in Q4 2018.
  • Rhenman & Partners Asset Management's portfolio value fell 12% quarter-over-quarter to $875M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.